<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE collection SYSTEM "BioC.dtd">
<collection><source>PMC</source><date>20220724</date><key>pmc.key</key><document><id>9291241</id><infon key="license">NO-CC CODE</infon><passage><infon key="article-id_doi">10.1016/j.jacc.2022.04.056</infon><infon key="article-id_pii">S0735-1097(22)05104-X</infon><infon key="article-id_pmc">9291241</infon><infon key="article-id_pmid">35863846</infon><infon key="fpage">299</infon><infon key="issue">4</infon><infon key="kwd">COVID-19 cytokines fulminant myocarditis multisystem inflammatory syndrome RNA polymerase III autoantibodies SARS-CoV-2 VA-ECMO CMR, cardiac magnetic resonance imaging ELISA, enzyme-linked immunosorbent assay EMB, endomyocardial biopsy ICU, intensive care unit IFN, interferon IgG, immunoglobulin G IL, interleukin LVEF, left ventricular ejection fraction MIS, multisystem inflammatory syndrome MIS-A, multisystem inflammatory syndrome in adults MIS-C, multisystem inflammatory syndrome in children PCA, principal component analysis RT-PCR, reverse transcription polymerase chain reaction SARS-CoV-2, severe acute respiratory syndrome-coronavirus-2 TNF, tumor necrosis factor VA-ECMO, venoarterial extracorporeal membrane oxygenation</infon><infon key="license">Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</infon><infon key="lpage">312</infon><infon key="name_0">surname:Barhoum;given-names:Petra</infon><infon key="name_1">surname:Pineton de Chambrun;given-names:Marc</infon><infon key="name_10">surname:Lebreton;given-names:Guillaume</infon><infon key="name_11">surname:Boussouar;given-names:Samia</infon><infon key="name_12">surname:Schmidt;given-names:Matthieu</infon><infon key="name_13">surname:Yssel;given-names:Hans</infon><infon key="name_14">surname:Lefevre;given-names:Lucie</infon><infon key="name_15">surname:Miyara;given-names:Makoto</infon><infon key="name_16">surname:Charuel;given-names:Jean-Luc</infon><infon key="name_17">surname:Marot;given-names:Stéphane</infon><infon key="name_18">surname:Marcelin;given-names:Anne-Geneviève</infon><infon key="name_19">surname:Luyt;given-names:Charles-Edouard</infon><infon key="name_2">surname:Dorgham;given-names:Karim</infon><infon key="name_20">surname:Leprince;given-names:Pascal</infon><infon key="name_21">surname:Amoura;given-names:Zahir</infon><infon key="name_22">surname:Montalescot;given-names:Gilles</infon><infon key="name_23">surname:Redheuil;given-names:Alban</infon><infon key="name_24">surname:Combes;given-names:Alain</infon><infon key="name_25">surname:Gorochov;given-names:Guy</infon><infon key="name_26">surname:Hékimian;given-names:Guillaume</infon><infon key="name_3">surname:Kerneis;given-names:Mathieu</infon><infon key="name_4">surname:Burrel;given-names:Sonia</infon><infon key="name_5">surname:Quentric;given-names:Paul</infon><infon key="name_6">surname:Parizot;given-names:Christophe</infon><infon key="name_7">surname:Chommeloux;given-names:Juliette</infon><infon key="name_8">surname:Bréchot;given-names:Nicolas</infon><infon key="name_9">surname:Moyon;given-names:Quentin</infon><infon key="section_type">TITLE</infon><infon key="title">Key Words Abbreviations and Acronyms</infon><infon key="type">front</infon><infon key="volume">80</infon><infon key="year">2022</infon><offset>0</offset><text>Phenotypic Heterogeneity of Fulminant COVID-19--Related Myocarditis in Adults</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>78</offset><text>Background</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>89</offset><text>Adults who have been infected with SARS-CoV-2 can develop a multisystem inflammatory syndrome (MIS-A), including fulminant myocarditis. Yet, several patients fail to meet MIS-A criteria, suggesting the existence of distinct phenotypes in fulminant COVID-19–related myocarditis.</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>369</offset><text>Objectives</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>380</offset><text>This study sought to compare the characteristics and clinical outcome between patients with fulminant COVID-19–related myocarditis fulfilling MIS-A criteria (MIS-A+) or not (MIS-A−).</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>567</offset><text>Methods</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>575</offset><text>A monocentric retrospective analysis of consecutive fulminant COVID-19–related myocarditis in a 26-bed intensive care unit (ICU).</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>707</offset><text>Results</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>715</offset><text>Between March 2020 and June 2021, 38 patients required ICU admission (male 66%; mean age 32 ± 15 years) for suspected fulminant COVID-19–related myocarditis. In-ICU treatment for organ failure included dobutamine 79%, norepinephrine 60%, mechanical ventilation 50%, venoarterial extracorporeal membrane oxygenation 42%, and renal replacement therapy 29%. In-hospital mortality was 13%. Twenty-five patients (66%) met the MIS-A criteria. MIS-A− patients compared with MIS-A+ patients were characterized by a shorter delay between COVID-19 symptoms onset and myocarditis, a lower left ventricular ejection fraction, and a higher rate of in-ICU organ failure, and were more likely to require mechanical circulatory support with venoarterial extracorporeal membrane oxygenation (92% vs 16%; P &lt; 0.0001). In-hospital mortality was higher in MIS-A− patients (31% vs 4%). MIS-A+ had higher circulating levels of interleukin (IL)-22, IL-17, and tumor necrosis factor-α (TNF-α), whereas MIS-A− had higher interferon-α2 (IFN-α2) and IL-8 levels. RNA polymerase III autoantibodies were present in 7 of 13 MIS-A− patients (54%) but in none of the MIS-A+ patients.</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>1884</offset><text>Conclusion</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>1895</offset><text>MIS-A+ and MIS-A− fulminant COVID-19–related myocarditis patients have 2 distinct phenotypes with different clinical presentations, prognosis, and immunological profiles. Differentiating these 2 phenotypes is relevant for patients’ management and further understanding of their pathophysiology.</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>2196</offset><text>Central Illustration</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>2217</offset><text>COVID-19–related myocarditis has been reported since the beginning of the severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) outbreak. Fulminant myocarditis is a rare, but life-threatening, form of myocarditis leading to significant morbidity and mortality especially in young patients. First described in children and subsequently in adults, the multisystem inflammatory syndrome (MIS-C and MIS-A, respectively) accounts for a large proportion of COVID-19–related myocarditis. The U.S. Centers for Disease Control and Prevention has developed case definition criteria to standardize its diagnosis. Yet, some patients do not meet these criteria, suggesting the existence of distinct phenotypes in COVID-19–related myocarditis. We conducted a study to compare the clinical, biological, and immunological characteristics of patients with fulminant COVID-19–related myocarditis meeting or not meeting MIS-A criteria.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_1</infon><offset>3149</offset><text>Methods</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>3157</offset><text>Patients and controls</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>3179</offset><text>We retrospectively reviewed the database of our 26-bed intensive care unit (ICU) between March 2020 and June 2021, and included all patients admitted for clinically suspected myocarditis with proven SARS-CoV-2 infection. Clinically suspected myocarditis was then adjudicated as definite or probable myocarditis according to the definition by Bonaca et al (Supplemental Appendix) following clinical investigations. Proven SARS-CoV-2 infection was confirmed by positive reverse transcription polymerase chain reaction (RT-PCR) in either nasopharyngeal aspirate, lower airway respiratory samples, or serum and/or positive serology showing the presence of circulating anti-nucleocapsid protein (anti-N) or anti-spike protein (anti-S) receptor binding domain antibodies in patients not vaccinated against COVID-19. All laboratory analyses were performed as the standard of care in the myocarditis workup of our institution. In addition, healthy SARS-CoV-2–negative individuals (n = 10) were included as control subjects for cytokine measurements.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>4226</offset><text>Data collection</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>4242</offset><text>The following information was collected on standardized forms: epidemiologic parameters; severity of underlying condition according to the McCabe–Jackson criteria; medical history; COVID-19 infection history, manifestations, and complications; MIS-A criteria (Supplemental Appendix); day 0 Sequential Organ Failure Assessment Score and Simplified Acute Physiology Score II; day 0 and in-ICU clinical and biological parameters; day 0 and in-ICU organ-failure support treatment; day 0, in-ICU, and last-follow-up echocardiography parameters; in-ICU cytokine profiling; in-ICU SARS-CoV-2 and myocarditis-specific treatment; in-ICU and follow-up computed tomography scan and cardiac magnetic resonance imaging (CMR); complications; and vital status at ICU and hospital discharge, as well as at last follow-up.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>5051</offset><text>SARS-CoV-2 RT-PCR and serological analyses</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>5094</offset><text>Detection of SARS-CoV-2 was carried out by RT-PCR in clinical specimens, using the Cobas6800 SARS-CoV-2 Test (Roche Diagnostics) and serological detection of immunoglobulin G (IgG) anti-N and IgG anti-S SARS-CoV-2, was performed by enzyme-linked immunosorbent assay (ELISA) on the Abbott platform (Abbott Diagnostics) in accordance with the manufacturer’s specifications.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>5468</offset><text>Cytokine measurement</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>5489</offset><text>Whole blood was collected in anticoagulant-free tubes, and serum was separated by centrifugation and stored at −80°C. Serum concentrations of interleukin (IL)-1β, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12p70, IL-22, interferon (IFN)-γ, and tumor necrosis factor (TNF)-α were measured on a Quanterix SP-X imaging and analysis platform using the Human CorPlex Cytokine Panel Array kit (Quanterix). Single-plex bead-based ultrasensitive immunodetection of IL-17A and IFN-α was performed by digital ELISA using the Simoa (single molecule array) HD-1 analyzer (Quanterix), according to the manufacturer’s instructions. Serum IFN-β levels were quantified using a highly sensitive ELISA kit (PBL Assay Science), according to the manufacturer’s instructions. Serum cytokine concentrations were interpolated from the correspondent calibration curve taking into account the dilution factor. All cytokine concentrations were expressed in pg/mL. Samples with nondetectable values or those above the detection range were replaced by the limit of detection value and the upper limit of quantification, respectively.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>6604</offset><text>Anti–IFN-α and RNA polymerase III autoantibodies</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>6657</offset><text>Autoantibodies against IFN-α were quantified using the anti–IFN-α Antibody Human ELISA Kit (Thermo Fisher, Invitrogen), according to the manufacturer's instructions. Calibrators were run in duplicate and fit with a 4-parameter logistic regression. The concentration of anti–IFN-α antibodies in samples was interpolated from the calibration curve by multiplying the obtained values with the dilution factor. The positivity threshold was 15 ng/mL. For RNA polymerase III autoantibodies screening, an indirect immunofluorescence assay was run on HEp-2000 cells (Immuno Concepts). When positive (≥1/80) and when the immunofluorescence labeling pattern was evocative of RNA polymerase III autoantibodies (fine-speckled nuclear-labeling pattern with small dots), a confirmatory immunodot assay (Euroline Systemic Sclerosis Test, Bio Advance) was carried out.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>7523</offset><text>Statistical analyses</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>7544</offset><text>Continuous variables are expressed as median (IQR: 25-75) and compared with Wilcoxon’s signed rank tests. Categorical variables are expressed as n (%) and compared with chi-square tests or Fisher exact tests. Cumulative probabilities of survival were calculated using the Kaplan-Meier method and compared with log-rank tests. A 2-tailed P value &lt; 0.05 was considered statistically significant. Analyses were computed with StatView software v5.0 (SAS Institute) and IBM SPSS Statistics v22.0 software (IBM Corp). Unsupervised principal component analysis (PCA) was performed using R software v3.6.2 with the FactoExtra and FactoMineR functions, on z-scaled log10-transformed cytokine concentrations. Samples with missing data were excluded from the PCA analysis for 1 MIS-A+ patient and 2 MIS-A− patients.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>8355</offset><text>Ethical considerations</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>8378</offset><text>This study was conducted in accordance with the declaration of Helsinki using the database registered at the Commission Nationale de l’Informatique et des Libertés (CNIL, registration no. 1950673). In agreement with the ethical standards of our hospital’s Institutional Review Board, the Committee for the Protection of Human Subjects, and French law, written informed consent was not needed for demographic, physiological, and hospital-outcome data analysis, because this observational study does not modify existing diagnostic or therapeutic strategies; however, patients and/or their relatives were informed of their anonymous inclusion in the study.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_1</infon><offset>9037</offset><text>Results</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>9045</offset><text>General patient characteristics</text></passage><passage><infon key="file">tbl1.xml</infon><infon key="id">tbl1</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>9077</offset><text>COVID-19–Related MIS-A Criteria and SARS-CoV-2 Tests Results</text></passage><passage><infon key="file">tbl1.xml</infon><infon key="id">tbl1</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;th/&gt;&lt;th&gt;All Patients (N = 38)&lt;/th&gt;&lt;th&gt;MIS-A&lt;sup&gt;−&lt;/sup&gt; (n = 13)&lt;/th&gt;&lt;th&gt;MIS-A&lt;sup&gt;+&lt;/sup&gt; (n = 25)&lt;/th&gt;&lt;th&gt;&lt;italic&gt;P&lt;/italic&gt; Value&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td&gt;Age, y&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;27.5 (19.0-37.0)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;33.0 (21.5-38.5)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;25.0 (18.5-35.5)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.3&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Women&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;13 (34)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;6 (46)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;7 (28)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.3&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;BMI, kg/m&lt;sup&gt;2&lt;/sup&gt;&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;24.8 (22.4-28.6)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;25.9 (23.3-28.9)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;24.7 (21.7-28.2)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.7&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Time from first COVID-19 symptoms to myocarditis, days&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;5 (0-26)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;3 (0-5)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;8 (2-38)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.04&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Time from myocarditis symptoms onset to ICU, days&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;3 (0-5)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;1 (0-3)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;4 (1-6)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.009&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICU admission SOFA score&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;8 (5-11)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;11 (8-13)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;6 (4-10)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.002&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICU admission SAPS-II score&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;30 (20-40)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;33 (25-49)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;25 (15-35)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.04&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MIS-A criteria&lt;xref rid=&quot;tbl1fna&quot; ref-type=&quot;table-fn&quot;&gt;a&lt;/xref&gt;&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Fever&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;36 (95)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;9 (69)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;25 (100)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.01&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Primary clinical criteria&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Myocardial involvement&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;38 (100)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;13 (100)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;25 (100)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;na&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Skin involvement&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;14 (37)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;1 (8)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;13 (52)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.01&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Secondary clinical criteria&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Neurological involvement&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;14 (37)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;4 (31)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;10 (40)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.5&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Shock or hypotension&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;36 (95)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;13 (100)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;23 (92)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.1&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Abdominal involvement&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;22 (58)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;7 (54)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;15 (60)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.7&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Platelets &amp;lt;150 × 10&lt;sup&gt;9&lt;/sup&gt;/L&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;10 (26)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;5 (38)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;5 (20)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.09&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Laboratory evidence&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Inflammation&lt;xref rid=&quot;tbl1fnb&quot; ref-type=&quot;table-fn&quot;&gt;b&lt;/xref&gt;&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;29 (76)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;2 (15)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;25 (100)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt;0.0001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Positive SARS-CoV-2 test&lt;xref rid=&quot;tbl1fnc&quot; ref-type=&quot;table-fn&quot;&gt;c&lt;/xref&gt;&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;38 (100)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;13 (100)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;25 (100)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;na&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SARS-CoV-2 tests&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Positive nasopharyngeal RT-PCR&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;14 (37)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;11 (85)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;4 (16)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt;0.0001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; CT value&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;26 (18-32)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;24 (18-28)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;32 (21-34)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.2&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Positive serology&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;26 (68)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;2 (15)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;24 (96)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt;0.0001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; IgG anti-S&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;25 (67)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;2 (15)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;23/24 (96)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt;0.0001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Titer, UA/mL&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;660 (156-1,440)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;2.3 (0.1-59)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;854 (528-2,575)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt;0.0001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; IgG anti-N&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;26 (68)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;2 (15)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;24 (96)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt;0.0001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Index, value&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;2.2 (0.1-5.3)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.4 (0.03-0.8)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;4.8 (2.2-5.5)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt;0.0001&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>9140</offset><text>	All Patients (N = 38)	MIS-A− (n = 13)	MIS-A+ (n = 25)	P Value	 	Age, y	27.5 (19.0-37.0)	33.0 (21.5-38.5)	25.0 (18.5-35.5)	0.3	 	Women	13 (34)	6 (46)	7 (28)	0.3	 	BMI, kg/m2	24.8 (22.4-28.6)	25.9 (23.3-28.9)	24.7 (21.7-28.2)	0.7	 	Time from first COVID-19 symptoms to myocarditis, days	5 (0-26)	3 (0-5)	8 (2-38)	0.04	 	Time from myocarditis symptoms onset to ICU, days	3 (0-5)	1 (0-3)	4 (1-6)	0.009	 	ICU admission SOFA score	8 (5-11)	11 (8-13)	6 (4-10)	0.002	 	ICU admission SAPS-II score	30 (20-40)	33 (25-49)	25 (15-35)	0.04	 	MIS-A criteriaa					 	 Fever	36 (95)	9 (69)	25 (100)	0.01	 	 Primary clinical criteria					 	 Myocardial involvement	38 (100)	13 (100)	25 (100)	na	 	 Skin involvement	14 (37)	1 (8)	13 (52)	0.01	 	 Secondary clinical criteria					 	 Neurological involvement	14 (37)	4 (31)	10 (40)	0.5	 	 Shock or hypotension	36 (95)	13 (100)	23 (92)	0.1	 	 Abdominal involvement	22 (58)	7 (54)	15 (60)	0.7	 	 Platelets &lt;150 × 109/L	10 (26)	5 (38)	5 (20)	0.09	 	 Laboratory evidence					 	 Inflammationb	29 (76)	2 (15)	25 (100)	&lt;0.0001	 	 Positive SARS-CoV-2 testc	38 (100)	13 (100)	25 (100)	na	 	SARS-CoV-2 tests					 	 Positive nasopharyngeal RT-PCR	14 (37)	11 (85)	4 (16)	&lt;0.0001	 	 CT value	26 (18-32)	24 (18-28)	32 (21-34)	0.2	 	 Positive serology	26 (68)	2 (15)	24 (96)	&lt;0.0001	 	 IgG anti-S	25 (67)	2 (15)	23/24 (96)	&lt;0.0001	 	 Titer, UA/mL	660 (156-1,440)	2.3 (0.1-59)	854 (528-2,575)	&lt;0.0001	 	 IgG anti-N	26 (68)	2 (15)	24 (96)	&lt;0.0001	 	 Index, value	2.2 (0.1-5.3)	0.4 (0.03-0.8)	4.8 (2.2-5.5)	&lt;0.0001	 	</text></passage><passage><infon key="file">tbl1.xml</infon><infon key="id">tbl1</infon><infon key="section_type">TABLE</infon><infon key="type">table_footnote</infon><offset>10697</offset><text>Values are median (IQR) or n (%). Continuous variables are compared with Wilcoxon’s rank test; categorical variables are compared with Fisher exact test.</text></passage><passage><infon key="file">tbl1.xml</infon><infon key="id">tbl1</infon><infon key="section_type">TABLE</infon><infon key="type">table_footnote</infon><offset>10853</offset><text>BMI = body mass index; CT = cycle threshold; ICU = intensive care unit; IgG = immunoglobulin G; MIS-A = multisystem inflammatory syndrome in adults; N = nucleocapsid protein; RT-PCR = reverse transcription polymerase-chain reaction; S = spike protein; SAPS-II = Simplified Acute Physiology Score-II; SARS-CoV-2 = severe acute respiratory syndrome-coronavirus-2; SOFA = Sequential Organ Failure Assessment.</text></passage><passage><infon key="file">tbl1.xml</infon><infon key="id">tbl1</infon><infon key="section_type">TABLE</infon><infon key="type">table_footnote</infon><offset>11281</offset><text>According the Centers for Disease Control and Prevention.</text></passage><passage><infon key="file">tbl1.xml</infon><infon key="id">tbl1</infon><infon key="section_type">TABLE</infon><infon key="type">table_footnote</infon><offset>11339</offset><text>Elevated levels of at least 2 of the following biomarkers including: C-reactive protein &gt;10 mg/L, procalcitonin &gt;1 ng/mL, fibrinogen &gt;5 g/L.</text></passage><passage><infon key="file">tbl1.xml</infon><infon key="id">tbl1</infon><infon key="section_type">TABLE</infon><infon key="type">table_footnote</infon><offset>11482</offset><text>Positive RT-PCR, serology, or antigen for SARS-CoV-2.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>11536</offset><text>Between March 2020 and June 2021, 38 patients requiring ICU admission for clinically suspected fulminant COVID-19–related myocarditis were included in this study. They were mostly men (66%) of young age (median age 27.5 years [IQR: 19-37 years]) with few comorbidities. Their baseline characteristics are reported in Table 1 and Supplemental Table 1. All had positive SARS-CoV-2 RT-PCR (37%) or serology (68%) with a median delay of 5 days between COVID-19 symptom onset and the first manifestation of myocarditis. None had previously received any COVID-19 vaccine. Most frequent symptoms were fever (95%), abdominal pain or nausea (60%), chest pain (47%), and dyspnea (42%).</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>12217</offset><text>At admission, patients had severely impaired left ventricular function (left ventricular ejection fraction [LVEF] 20% [IQR: 14%-37%], LVOT-VTI 11 cm [IQR: 6-15 cm]), an increased high-sensitivity T-troponin (median 1,300 ng/mL [IQR: 486-4,750 ng/mL]), and 79% presented with cardiogenic shock. When performed (n = 10), coronary angiography was normal. COVID-19 pneumonia was noted on computed tomography scan examination in 29% of cases. In the 26 patients who had CMR evaluation, myocardial edema, and late gadolinium enhancement were reported in 73% and 54%, respectively.</text></passage><passage><infon key="file">tbl2.xml</infon><infon key="id">tbl2</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>12794</offset><text>Fulminant COVID-19–Related Myocarditis Findings</text></passage><passage><infon key="file">tbl2.xml</infon><infon key="id">tbl2</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;th/&gt;&lt;th&gt;n&lt;xref rid=&quot;tbl2fna&quot; ref-type=&quot;table-fn&quot;&gt;a&lt;/xref&gt;&lt;/th&gt;&lt;th&gt;All Patients (N = 38)&lt;/th&gt;&lt;th&gt;MIS-A&lt;sup&gt;−&lt;/sup&gt; (n = 13)&lt;/th&gt;&lt;th&gt;MIS-A&lt;sup&gt;+&lt;/sup&gt; (n = 25)&lt;/th&gt;&lt;th&gt;&lt;italic&gt;P&lt;/italic&gt; Value&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td&gt;Clinical symptoms&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Chest pain&lt;/td&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;18 (47)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;9 (69)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;9 (36)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.09&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Faintness&lt;/td&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;4 (10)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;4 (31)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0 (0)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.01&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Syncope&lt;/td&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;2 (5)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;1 (8)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;1 (4)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;1.0&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Sudden death&lt;/td&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;1 (3)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;1 (8)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0 (0)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.3&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Laboratory findings&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Troponin, ng/mL&lt;/td&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;526 (224-1,227)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;441 (177-1,089)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;712 (217-2,025)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.2&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Highest value in ICU&lt;/td&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;1,300 (486-4,750)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;2,836 (450-9,634)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;1,000 (471-3,036)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.2&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; NT-proBNP, ng/L&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;1&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;9,931 (2,367-23,934)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;2,755 (1,044-8,271)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;12,525 (7,000-32,500)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.007&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Creatine phosphokinase, UI/L&lt;/td&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;312 (131-1,150)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;586 (388-1,802)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;190 (115-435)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.003&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Electrocardiogram findings&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Normal electrocardiogram&lt;/td&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;14 (37)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;5 (38)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;9 (36)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;1.0&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Sinus rhythm&lt;/td&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;36 (95)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;12 (92)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;24 (96)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;1.0&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Atrial fibrillation&lt;/td&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;2 (5)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;1 (8)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;1 (4)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;1.0&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; ST-segment elevation&lt;/td&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;10 (26)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;6 (46)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;4 (16)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.06&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; ST-segment depression&lt;/td&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;6 (16)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;2 (15)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;4 (16)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;1.0&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Negative T wave&lt;/td&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;10 (26)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;1 (8)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;9 (36)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.1&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Complete heart block&lt;/td&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;1 (3)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0 (0)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;1 (4)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;1.0&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Bundle branch block&lt;/td&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;5 (13)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;1 (8)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;4 (16)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.6&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Ventricular rhythm disorders&lt;/td&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;3 (8)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;3 (23)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0 (0)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.03&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Echocardiography findings&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; LVEF, %&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; First evaluation&lt;/td&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;30 (20-45)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;30 (15-45)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;30 (25-42)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.5&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; On ICU admission&lt;/td&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;20 (14-37)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;10 (5-30)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;30 (15-45)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.01&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Lowest value in ICU&lt;/td&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;20 (10-30)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;10 (5-25)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;20 (15-30)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.02&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; ICU discharge&lt;/td&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;42 (30-54)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;35 (17-57)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;45 (35-52)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.1&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Last follow-up&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;10&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;60 (50-64)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;59 (44-60)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;60 (50-65)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.5&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; LVOT VTI, cm&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; First evaluation&lt;/td&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;12 (8-16)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;8 (7-17)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;12 (9-15)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.2&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; On ICU admission&lt;/td&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;11 (6-15)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;5 (2-9)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;13 (10-17)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt;0.0001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; ICU discharge&lt;/td&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;17 (12-18)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;12 (7-18)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;17 (15-19)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.08&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Ventricular hypertrophy&lt;/td&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;16 (42)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;8 (62)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;8 (32)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.1&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Ventricular dilation&lt;/td&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;5 (13)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;2 (15)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;3 (12)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;1.0&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; LVEDD, mm&lt;/td&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;50 (47-56)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;48 (46-55)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;50 (47-56)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.7&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Right ventricular involvement&lt;/td&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;15 (39)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;7 (54)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;8 (32)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.3&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; TAPSE, mm&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;20&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;14 (12-17)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;12 (8-16)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;14 (12-17)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.2&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; S wave, cm/s&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;21&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;9 (7-11)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;6 (1-11)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;10 (8-11)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.1&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Mitral valve regurgitation&lt;/td&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;9 (24)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;3 (23)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;6 (24)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;1.0&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Aortic valve regurgitation&lt;/td&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;3 (8)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0 (0)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;1 (4)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;1.0&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Tricuspid valve regurgitation&lt;/td&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;3 (8)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0 (0)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;3 (12)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.5&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Pericardial effusion&lt;/td&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;15 (39)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;8 (62)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;7 (28)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.08&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Pericardiocentesis&lt;/td&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;4 (10)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;4 (31)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0 (0)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.01&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;CMR findings&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Number performed in ICU/hospital&lt;/td&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;26 (68)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;5 (38)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;21 (84)&lt;/td&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Time from symptoms to CMR, days&lt;/td&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;7 (4-18)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;16 (9-33)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;5 (4-10)&lt;/td&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Myocardial edema&lt;/td&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;19/26 (73)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;3/5 (60)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;16/21 (76)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.6&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Late gadolinium enhancement&lt;/td&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;14/26 (54)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;4/5 (80)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;10/21 (48)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.3&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Myocarditis classification&lt;xref rid=&quot;tbl2fnb&quot; ref-type=&quot;table-fn&quot;&gt;b&lt;/xref&gt;&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Definite myocarditis&lt;/td&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;29 (76)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;9 (69)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;20 (80)&lt;/td&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Probable myocarditis&lt;/td&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;9 (24)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;4 (31)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;5 (20)&lt;/td&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Pathology&lt;/td&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;2 (5)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;2 (15)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;1 (4)&lt;/td&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Imaging&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Cardiac magnetic resonance&lt;/td&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;22 (58)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;4 (31)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;18 (72)&lt;/td&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Echocardiography WMA&lt;/td&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;32 (84)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;13 (100)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;24 (96)&lt;/td&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Coronary angiography performed and normal&lt;/td&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;10 (26)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;6 (46)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;4 (16)&lt;/td&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Electrocardiogram&lt;/td&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;23 (60)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;8 (61)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;15 (60)&lt;/td&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Syndrome&lt;/td&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;38 (100)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;13 (100)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;25 (100)&lt;/td&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Biomarkers&lt;/td&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;38 (100)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;13 (100)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;25 (100)&lt;/td&gt;&lt;td/&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>12844</offset><text>	na	All Patients (N = 38)	MIS-A− (n = 13)	MIS-A+ (n = 25)	P Value	 	Clinical symptoms						 	 Chest pain		18 (47)	9 (69)	9 (36)	0.09	 	 Faintness		4 (10)	4 (31)	0 (0)	0.01	 	 Syncope		2 (5)	1 (8)	1 (4)	1.0	 	 Sudden death		1 (3)	1 (8)	0 (0)	0.3	 	Laboratory findings						 	 Troponin, ng/mL		526 (224-1,227)	441 (177-1,089)	712 (217-2,025)	0.2	 	 Highest value in ICU		1,300 (486-4,750)	2,836 (450-9,634)	1,000 (471-3,036)	0.2	 	 NT-proBNP, ng/L	1	9,931 (2,367-23,934)	2,755 (1,044-8,271)	12,525 (7,000-32,500)	0.007	 	 Creatine phosphokinase, UI/L		312 (131-1,150)	586 (388-1,802)	190 (115-435)	0.003	 	Electrocardiogram findings						 	 Normal electrocardiogram		14 (37)	5 (38)	9 (36)	1.0	 	 Sinus rhythm		36 (95)	12 (92)	24 (96)	1.0	 	 Atrial fibrillation		2 (5)	1 (8)	1 (4)	1.0	 	 ST-segment elevation		10 (26)	6 (46)	4 (16)	0.06	 	 ST-segment depression		6 (16)	2 (15)	4 (16)	1.0	 	 Negative T wave		10 (26)	1 (8)	9 (36)	0.1	 	 Complete heart block		1 (3)	0 (0)	1 (4)	1.0	 	 Bundle branch block		5 (13)	1 (8)	4 (16)	0.6	 	 Ventricular rhythm disorders		3 (8)	3 (23)	0 (0)	0.03	 	Echocardiography findings						 	 LVEF, %						 	 First evaluation		30 (20-45)	30 (15-45)	30 (25-42)	0.5	 	 On ICU admission		20 (14-37)	10 (5-30)	30 (15-45)	0.01	 	 Lowest value in ICU		20 (10-30)	10 (5-25)	20 (15-30)	0.02	 	 ICU discharge		42 (30-54)	35 (17-57)	45 (35-52)	0.1	 	 Last follow-up	10	60 (50-64)	59 (44-60)	60 (50-65)	0.5	 	 LVOT VTI, cm						 	 First evaluation		12 (8-16)	8 (7-17)	12 (9-15)	0.2	 	 On ICU admission		11 (6-15)	5 (2-9)	13 (10-17)	&lt;0.0001	 	 ICU discharge		17 (12-18)	12 (7-18)	17 (15-19)	0.08	 	 Ventricular hypertrophy		16 (42)	8 (62)	8 (32)	0.1	 	 Ventricular dilation		5 (13)	2 (15)	3 (12)	1.0	 	 LVEDD, mm		50 (47-56)	48 (46-55)	50 (47-56)	0.7	 	 Right ventricular involvement		15 (39)	7 (54)	8 (32)	0.3	 	 TAPSE, mm	20	14 (12-17)	12 (8-16)	14 (12-17)	0.2	 	 S wave, cm/s	21	9 (7-11)	6 (1-11)	10 (8-11)	0.1	 	 Mitral valve regurgitation		9 (24)	3 (23)	6 (24)	1.0	 	 Aortic valve regurgitation		3 (8)	0 (0)	1 (4)	1.0	 	 Tricuspid valve regurgitation		3 (8)	0 (0)	3 (12)	0.5	 	 Pericardial effusion		15 (39)	8 (62)	7 (28)	0.08	 	 Pericardiocentesis		4 (10)	4 (31)	0 (0)	0.01	 	CMR findings						 	 Number performed in ICU/hospital		26 (68)	5 (38)	21 (84)		 	 Time from symptoms to CMR, days		7 (4-18)	16 (9-33)	5 (4-10)		 	 Myocardial edema		19/26 (73)	3/5 (60)	16/21 (76)	0.6	 	 Late gadolinium enhancement		14/26 (54)	4/5 (80)	10/21 (48)	0.3	 	Myocarditis classificationb						 	 Definite myocarditis		29 (76)	9 (69)	20 (80)		 	 Probable myocarditis		9 (24)	4 (31)	5 (20)		 	 Pathology		2 (5)	2 (15)	1 (4)		 	 Imaging						 	 Cardiac magnetic resonance		22 (58)	4 (31)	18 (72)		 	 Echocardiography WMA		32 (84)	13 (100)	24 (96)		 	 Coronary angiography performed and normal		10 (26)	6 (46)	4 (16)		 	 Electrocardiogram		23 (60)	8 (61)	15 (60)		 	 Syndrome		38 (100)	13 (100)	25 (100)		 	 Biomarkers		38 (100)	13 (100)	25 (100)		 	</text></passage><passage><infon key="file">tbl2.xml</infon><infon key="id">tbl2</infon><infon key="section_type">TABLE</infon><infon key="type">table_footnote</infon><offset>15855</offset><text>Values are median (IQR), n (%), or n/N (%), unless otherwise indicated. Continuous variables are compared with Wilcoxon’s rank test; categorical variables are compared with Fisher exact test.</text></passage><passage><infon key="file">tbl2.xml</infon><infon key="id">tbl2</infon><infon key="section_type">TABLE</infon><infon key="type">table_footnote</infon><offset>16049</offset><text>CMR = cardiac magnetic resonance; LVEDD = left ventricular end-diastolic diameter; LVEF = left ventricular ejection fraction; LVOT VTI = left ventricle outflow tract velocity-time integral; NT-proBNP = N-terminal pro–B-type natriuretic peptide; TAPSE = tricuspid annular plane systolic excursion; WMA = wall motion abnormality; other abbreviations as in Table 1.</text></passage><passage><infon key="file">tbl2.xml</infon><infon key="id">tbl2</infon><infon key="section_type">TABLE</infon><infon key="type">table_footnote</infon><offset>16429</offset><text>Number of missing values.</text></passage><passage><infon key="file">tbl2.xml</infon><infon key="id">tbl2</infon><infon key="section_type">TABLE</infon><infon key="type">table_footnote</infon><offset>16455</offset><text>According to the myocarditis classification proposed by Bonaca et al.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>16526</offset><text>Three patients without recovery of cardiac function underwent myocardial biopsy. None were CMR-guided, as all were taken under mechanical circulatory support. Two surgical biopsies were taken in patients during venoarterial extracorporeal membrane oxygenation (VA-ECMO) centralization. The first one was an apical surgical biopsy in a patient cannulated under cardiopulmonary resuscitation, which was inconclusive. The second surgical biopsy highlighted myocarditis with an inflammatory infiltrate associated with myocyte dystrophy and edema. SARS-CoV-2 RT-PCR was negative, and electron microscopy analysis failed to identify viral particles in cardiomyocytes despite active myocarditis lesions on the evaluated sample. The last biopsy was endomyocardial and disclosed a mild lymphohistiocytic myocarditis with no edema, but with severe necrosis. SARS-CoV-2 RT-PCR was negative. Twenty-nine patients (76%) met the Bonaca classification criteria for definite myocarditis, whereas the others had probable myocarditis (Table 2 ).</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>17555</offset><text>In-ICU evolution and outcomes</text></passage><passage><infon key="file">tbl3.xml</infon><infon key="id">tbl3</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>17585</offset><text>Organ Failure Support, Myocarditis Treatment, Complications, and Outcome in ICU</text></passage><passage><infon key="file">tbl3.xml</infon><infon key="id">tbl3</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;th/&gt;&lt;th&gt;All Patients (N = 38)&lt;/th&gt;&lt;th&gt;MIS-A&lt;sup&gt;−&lt;/sup&gt; (n = 13)&lt;/th&gt;&lt;th&gt;MIS-A&lt;sup&gt;+&lt;/sup&gt; (n = 25)&lt;/th&gt;&lt;th&gt;&lt;italic&gt;P&lt;/italic&gt; Value&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td&gt;Time in ICU, days&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;6 (4-16)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;12 (7-30)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;5 (2-6)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt;0.0001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Cardiac arrest before ICU&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;1 (3)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;1 (8)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0 (0)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.3&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Organ failure support in ICU&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Dobutamine&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;30 (79)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;12 (92)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;18 (72)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.2&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Norepinephrine&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;23 (60)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;12 (92)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;11 (44)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.005&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Mechanical ventilation&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;19 (50)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;11 (85)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;8 (32)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.005&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Time on mechanical ventilation, days&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;15 (6-28)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;15 (8-35)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;11 (4-25)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.3&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Renal replacement therapy&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;11 (29)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;8 (61)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;3 (12)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.003&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; VA-ECMO&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;16 (42)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;12 (92)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;4 (16)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt;0.0001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; VA-ECMO under CPR&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;4 (11)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;4 (31)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0 (0)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.02&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Time on VA-ECMO, days&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;7 (5-12)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;8 (6-12)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;5 (4-12)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.1&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Time from admission to VA-ECMO, days&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;1 (0-1)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0 (0-1)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;1 (0-5)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.4&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; VV-ECMO&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;4 (10)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;2 (15)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;2 (8)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.6&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Time on VV-ECMO, days&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;18 (14-29)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;24 (16-24)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;17 (14-17)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.4&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Myocarditis treatment in ICU&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Corticosteroids&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;28 (74)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;7 (54)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;21 (84)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.06&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Intravenous immunoglobulins&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;27 (71)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;8 (61)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;19 (76)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.5&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Tocilizumab&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0 (0)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0 (0)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0 (0)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;Na&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Outcome&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; In-ICU mortality&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;5 (13)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;4 (31)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;1 (4)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.04&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; In-hospital mortality&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;5 (13)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;4 (31)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;1 (4)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.04&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; 3-month probability of survival, %&lt;xref rid=&quot;tbl3fna&quot; ref-type=&quot;table-fn&quot;&gt;a&lt;/xref&gt;&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;86 ± 6&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;68 ± 13&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;96 ± 4&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.01&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>17665</offset><text>	All Patients (N = 38)	MIS-A− (n = 13)	MIS-A+ (n = 25)	P Value	 	Time in ICU, days	6 (4-16)	12 (7-30)	5 (2-6)	&lt;0.0001	 	Cardiac arrest before ICU	1 (3)	1 (8)	0 (0)	0.3	 	Organ failure support in ICU					 	 Dobutamine	30 (79)	12 (92)	18 (72)	0.2	 	 Norepinephrine	23 (60)	12 (92)	11 (44)	0.005	 	 Mechanical ventilation	19 (50)	11 (85)	8 (32)	0.005	 	 Time on mechanical ventilation, days	15 (6-28)	15 (8-35)	11 (4-25)	0.3	 	 Renal replacement therapy	11 (29)	8 (61)	3 (12)	0.003	 	 VA-ECMO	16 (42)	12 (92)	4 (16)	&lt;0.0001	 	 VA-ECMO under CPR	4 (11)	4 (31)	0 (0)	0.02	 	 Time on VA-ECMO, days	7 (5-12)	8 (6-12)	5 (4-12)	0.1	 	 Time from admission to VA-ECMO, days	1 (0-1)	0 (0-1)	1 (0-5)	0.4	 	 VV-ECMO	4 (10)	2 (15)	2 (8)	0.6	 	 Time on VV-ECMO, days	18 (14-29)	24 (16-24)	17 (14-17)	0.4	 	Myocarditis treatment in ICU					 	 Corticosteroids	28 (74)	7 (54)	21 (84)	0.06	 	 Intravenous immunoglobulins	27 (71)	8 (61)	19 (76)	0.5	 	 Tocilizumab	0 (0)	0 (0)	0 (0)	Na	 	Outcome					 	 In-ICU mortality	5 (13)	4 (31)	1 (4)	0.04	 	 In-hospital mortality	5 (13)	4 (31)	1 (4)	0.04	 	 3-month probability of survival, %a	86 ± 6	68 ± 13	96 ± 4	0.01	 	</text></passage><passage><infon key="file">tbl3.xml</infon><infon key="id">tbl3</infon><infon key="section_type">TABLE</infon><infon key="type">table_footnote</infon><offset>18835</offset><text>Values are median (IQR), n (%), or mean ± SD. Continuous variables are compared with Wilcoxon’s rank test; categorical variables are compared with Fisher exact test.</text></passage><passage><infon key="file">tbl3.xml</infon><infon key="id">tbl3</infon><infon key="section_type">TABLE</infon><infon key="type">table_footnote</infon><offset>19004</offset><text>CPR = cardiopulmonary resuscitation; VA-ECMO = venoarterial extracorporeal membrane oxygenation; VV-ECMO = venovenous extracorporeal membrane oxygenation; other abbreviations as in Table 1.</text></passage><passage><infon key="file">tbl3.xml</infon><infon key="id">tbl3</infon><infon key="section_type">TABLE</infon><infon key="type">table_footnote</infon><offset>19195</offset><text>Probability of survival were calculated using Kaplan-Meier method and compared with log-tank tests.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>19295</offset><text>Median length of stay in ICU was 6 days. Seventy-nine percent of the patients received dobutamine, 60% norepinephrine, 50% mechanical ventilation, and 29% renal replacement therapy (Table 3 ). Four patients had a large pericardial effusion requiring drainage. Sixteen patients (42%) required mechanical circulatory support with VA-ECMO 1 day (IQR: 0-1 day) following ICU admission, for a median duration of 7 days. Twenty-eight (74%) were treated with corticosteroids, and 27 (74%), with intravenous immunoglobulins. In-hospital mortality was 13%. None of the survivors required cardiac transplantation or long-term ventricular assist device implantation. Among the 5 deceased patients, all had multiorgan failure before VA-ECMO implantation, including 3 cannulations during cardiopulmonary resuscitation. None could be weaned from VA-ECMO because of severe cardiac dysfunction. Median LVEF at ICU and hospital discharge was 42% (IQR: 30%-54%) and 60% (IQR: 50%-64%), respectively. Twenty-one survivors (64%) received beta-blockers at discharge, and 25 (76%) were treated with angiotensin-converting enzyme inhibitors, until distant evaluation with a cardiologist. At the last follow-up (median: 235 days [IQR: 155-359 days]), 32 patients were alive, and all but 1 had a normal LVEF. One patient was lost to follow-up.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>20617</offset><text>Comparison between MIS-A+ and MIS-A− patients</text></passage><passage><infon key="file">tbl4.xml</infon><infon key="id">tbl4</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>20665</offset><text>Laboratory Findings and Cytokine Profiling in the ICU</text></passage><passage><infon key="file">tbl4.xml</infon><infon key="id">tbl4</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;th&gt;Day 0 Laboratory Findings&lt;/th&gt;&lt;th&gt;n&lt;xref rid=&quot;tbl4fna&quot; ref-type=&quot;table-fn&quot;&gt;a&lt;/xref&gt;&lt;/th&gt;&lt;th&gt;All Patients (N = 38)&lt;/th&gt;&lt;th&gt;MIS-A&lt;sup&gt;−&lt;/sup&gt; (n = 13)&lt;/th&gt;&lt;th&gt;MIS-A&lt;sup&gt;+&lt;/sup&gt; (n = 25)&lt;/th&gt;&lt;th&gt;&lt;italic&gt;P&lt;/italic&gt; Value&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td&gt;Hemogram and hemostasis&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Leukocytes, 10&lt;sup&gt;9&lt;/sup&gt;/L&lt;/td&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;12.6 (9.2-19.7)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;8.7 (5.7-11.4)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;18.5 (11.7-21.0)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt;0.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Lymphocytes, 10&lt;sup&gt;9&lt;/sup&gt;/L&lt;/td&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;0.8 (0.5-1.5)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;1.2 (0.6-2.3)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.8 (0.5-1.2)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.08&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Polymorphonuclear cells, 10&lt;sup&gt;9&lt;/sup&gt;/L&lt;/td&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;10.7 (5.8-18.0)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;5.8 (3.4-8.1)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;15.6 (10.3-19.0)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt;0.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Hemoglobin, g/dL&lt;/td&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;12,1 (11.1-13.5)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;12.5 (10.4-16.0)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;12 (11.6-13.3)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.8&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Platelets 10&lt;sup&gt;9&lt;/sup&gt;/L&lt;/td&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;192 (152-247)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;192 (92-258)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;206 (160-243)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.7&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Prothrombin time, %&lt;/td&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;72 (64-81)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;65 (56-90)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;72 (69-77)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.4&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; D-dimers, μg/L&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;3&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;3,860 (1,290-6,700)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;2,500 (396-20,000)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;4,217 (1,602-6,035)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.6&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Inflammatory parameters&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; C-reactive protein, mg/L&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;5&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;257 (110-329)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;5 (4-72)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;277 (226-376)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt;0.0001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Procalcitonin, ng/mL&lt;/td&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;7.4 (0.5-46)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.2 (0.1-1.1)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;12.8 (3.7-65)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt;0.0001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Fibrinogen, g/L&lt;/td&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;6.8 (4.2-8.5)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;3.2 (2.2-4.3)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;7.9 (6.8-9.2)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt;0.0001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Biochemical findings&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Serum creatinine, μmol/L&lt;/td&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;105 (69-156)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;85 (60-105)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;134 (71-265)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.038&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; LDH, IU/L&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;2&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;419 (315-634)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;619 (320-973)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;385 (307-526)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.2&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; AST, IU/L&lt;/td&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;83 (46-139)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;70 (42-168)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;94 (46-129)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.9&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; ALT, IU/L&lt;/td&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;50 (32-101)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;39 (26-110)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;60 (37-101)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.4&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Serum total bilirubin, μmol/L&lt;/td&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;11 (8-19)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;6 (4-14)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;12 (10-21)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.006&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; pH&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;1&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;7.43 (7.30-7.46)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;7.31 (7.15-7.42)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;7.44 (7.41-7.47)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.004&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; pO&lt;sub&gt;2&lt;/sub&gt;, mm Hg&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;1&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;90 (70-120)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;106 (80-235)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;81 (69-99)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.06&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; pCO&lt;sub&gt;2&lt;/sub&gt;, mm Hg&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;1&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;30 (24-36)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;29 (20-46)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;30 (27-36)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.7&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Serum bicarbonates, mmol/L&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;2&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;19 (15-23)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;16 (10.4-19.4)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;21 (17-24)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.005&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Arterial lactate, mmol/L&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;2&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;2.5 (1.7-3.9)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;5.5 (1.8-8.2)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;2.1 (1.5-2.7)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.009&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Highest value in ICU, mmol/L&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;2&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;3.1 (2.4-7.1)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;7.5 (5.2-15.5)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;2.7 (1.7-3.4)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt;0.0001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Serum protein, g/L&lt;/td&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;61 (52-68)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;51 (40-57)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;65 (58-70)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt;0.0001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Serum albumin, g/L&lt;/td&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;25 (22-28)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;27 (23-33)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;25 (20-27)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.1&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Triglycerides, mmol/L&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;15&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;2 (1.7-3)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;2.0 (1.1-3.0)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;2.3 (1.8-3.2)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.4&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Immunological findings&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; RNA polymerase 3 autoantibodies&lt;/td&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;7 (18)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;7 (54)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0 (0)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Serum cytokine levels in ICU&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; IL-12p70, pg/mL&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;3&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.03 (0.01-0.4)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.03 (0.01-0.1)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.03 (0.01-0.4)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.3&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; IL-1β, pg/mL&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;3&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.2 (0.02-0.4)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.3 (0.01-0.9)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.2 (0.02-0.3)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.5&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; IL-4, pg/mL&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;3&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.4 (0.2-1.1)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.3 (0.3-0.5)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.6 (0.2-2.1)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.3&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; IL-5, pg/mL&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;3&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.1 (0.01-0.5)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.04 (0.01-0.6)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.3 (0.06-0.6)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.1&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; IFN-γ, pg/mL&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;3&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.4 (0.2-2.2)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.4 (0.09-2.0)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;1.2 (0.2-2.6)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.2&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; IL-6, pg/mL&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;3&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;55.2 (25.1-207.6)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;39.6 (16.6-225.4)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;57.8 (26.9-198.9)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.7&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; IL-8, pg/mL&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;3&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;82.7 (58.2-166.4)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;158.7 (74.9-784.2)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;65.7 (55.7-118.3)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.02&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; IL-22, pg/mL&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;3&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;6.4 (2.3-15.7)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;1.5 (0.7-2.9)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;9.93 (5.28-28.99)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt;0.0001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; TNF-α, pg/mL&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;3&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;14.2 (8.9-38.1)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;8.0 (4.9-34.0)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;21.1 (9.9-41.9)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.05&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; IL-10, pg/mL&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;3&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;50.3 (15.9-76.6)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;67.8 (20.1-143.1)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;44.2 (12.8-68.4)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.3&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; IL-17A, pg/mL&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;3&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;1.6 (0.2-5.2)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.15 (0.08-0.3)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;3.2 (0.8-6.2)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt;0.0001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; IFN-α2, pg/mL&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;3&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.02 (0.005-1.3)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;2.4 (0.2-15.0)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.013 (0.002-0.04)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; IFN-β, pg/mL&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;4&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.6 (0.6-0.6)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.6 (0.6-1.8)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.6 (0.6-0.6)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.2&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; Anti-IFNα autoantibodies&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;4&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;5 (15)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;1 (10)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;4 (17)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;1&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>20719</offset><text>Day 0 Laboratory Findings	na	All Patients (N = 38)	MIS-A− (n = 13)	MIS-A+ (n = 25)	P Value	 	Hemogram and hemostasis						 	 Leukocytes, 109/L		12.6 (9.2-19.7)	8.7 (5.7-11.4)	18.5 (11.7-21.0)	&lt;0.001	 	 Lymphocytes, 109/L		0.8 (0.5-1.5)	1.2 (0.6-2.3)	0.8 (0.5-1.2)	0.08	 	 Polymorphonuclear cells, 109/L		10.7 (5.8-18.0)	5.8 (3.4-8.1)	15.6 (10.3-19.0)	&lt;0.001	 	 Hemoglobin, g/dL		12,1 (11.1-13.5)	12.5 (10.4-16.0)	12 (11.6-13.3)	0.8	 	 Platelets 109/L		192 (152-247)	192 (92-258)	206 (160-243)	0.7	 	 Prothrombin time, %		72 (64-81)	65 (56-90)	72 (69-77)	0.4	 	 D-dimers, μg/L	3	3,860 (1,290-6,700)	2,500 (396-20,000)	4,217 (1,602-6,035)	0.6	 	Inflammatory parameters						 	 C-reactive protein, mg/L	5	257 (110-329)	5 (4-72)	277 (226-376)	&lt;0.0001	 	 Procalcitonin, ng/mL		7.4 (0.5-46)	0.2 (0.1-1.1)	12.8 (3.7-65)	&lt;0.0001	 	 Fibrinogen, g/L		6.8 (4.2-8.5)	3.2 (2.2-4.3)	7.9 (6.8-9.2)	&lt;0.0001	 	Biochemical findings						 	 Serum creatinine, μmol/L		105 (69-156)	85 (60-105)	134 (71-265)	0.038	 	 LDH, IU/L	2	419 (315-634)	619 (320-973)	385 (307-526)	0.2	 	 AST, IU/L		83 (46-139)	70 (42-168)	94 (46-129)	0.9	 	 ALT, IU/L		50 (32-101)	39 (26-110)	60 (37-101)	0.4	 	 Serum total bilirubin, μmol/L		11 (8-19)	6 (4-14)	12 (10-21)	0.006	 	 pH	1	7.43 (7.30-7.46)	7.31 (7.15-7.42)	7.44 (7.41-7.47)	0.004	 	 pO2, mm Hg	1	90 (70-120)	106 (80-235)	81 (69-99)	0.06	 	 pCO2, mm Hg	1	30 (24-36)	29 (20-46)	30 (27-36)	0.7	 	 Serum bicarbonates, mmol/L	2	19 (15-23)	16 (10.4-19.4)	21 (17-24)	0.005	 	 Arterial lactate, mmol/L	2	2.5 (1.7-3.9)	5.5 (1.8-8.2)	2.1 (1.5-2.7)	0.009	 	 Highest value in ICU, mmol/L	2	3.1 (2.4-7.1)	7.5 (5.2-15.5)	2.7 (1.7-3.4)	&lt;0.0001	 	 Serum protein, g/L		61 (52-68)	51 (40-57)	65 (58-70)	&lt;0.0001	 	 Serum albumin, g/L		25 (22-28)	27 (23-33)	25 (20-27)	0.1	 	 Triglycerides, mmol/L	15	2 (1.7-3)	2.0 (1.1-3.0)	2.3 (1.8-3.2)	0.4	 	Immunological findings						 	 RNA polymerase 3 autoantibodies		7 (18)	7 (54)	0 (0)	0.001	 	 Serum cytokine levels in ICU						 	 IL-12p70, pg/mL	3	0.03 (0.01-0.4)	0.03 (0.01-0.1)	0.03 (0.01-0.4)	0.3	 	 IL-1β, pg/mL	3	0.2 (0.02-0.4)	0.3 (0.01-0.9)	0.2 (0.02-0.3)	0.5	 	 IL-4, pg/mL	3	0.4 (0.2-1.1)	0.3 (0.3-0.5)	0.6 (0.2-2.1)	0.3	 	 IL-5, pg/mL	3	0.1 (0.01-0.5)	0.04 (0.01-0.6)	0.3 (0.06-0.6)	0.1	 	 IFN-γ, pg/mL	3	0.4 (0.2-2.2)	0.4 (0.09-2.0)	1.2 (0.2-2.6)	0.2	 	 IL-6, pg/mL	3	55.2 (25.1-207.6)	39.6 (16.6-225.4)	57.8 (26.9-198.9)	0.7	 	 IL-8, pg/mL	3	82.7 (58.2-166.4)	158.7 (74.9-784.2)	65.7 (55.7-118.3)	0.02	 	 IL-22, pg/mL	3	6.4 (2.3-15.7)	1.5 (0.7-2.9)	9.93 (5.28-28.99)	&lt;0.0001	 	 TNF-α, pg/mL	3	14.2 (8.9-38.1)	8.0 (4.9-34.0)	21.1 (9.9-41.9)	0.05	 	 IL-10, pg/mL	3	50.3 (15.9-76.6)	67.8 (20.1-143.1)	44.2 (12.8-68.4)	0.3	 	 IL-17A, pg/mL	3	1.6 (0.2-5.2)	0.15 (0.08-0.3)	3.2 (0.8-6.2)	&lt;0.0001	 	 IFN-α2, pg/mL	3	0.02 (0.005-1.3)	2.4 (0.2-15.0)	0.013 (0.002-0.04)	0.001	 	 IFN-β, pg/mL	4	0.6 (0.6-0.6)	0.6 (0.6-1.8)	0.6 (0.6-0.6)	0.2	 	 Anti-IFNα autoantibodies	4	5 (15)	1 (10)	4 (17)	1	 	</text></passage><passage><infon key="file">tbl4.xml</infon><infon key="id">tbl4</infon><infon key="section_type">TABLE</infon><infon key="type">table_footnote</infon><offset>23717</offset><text>Values are median (IQR) or n (%), unless otherwise indicated. Continuous variables are compared with Wilcoxon’s rank test; categorical variables are compared with Fisher exact test.</text></passage><passage><infon key="file">tbl4.xml</infon><infon key="id">tbl4</infon><infon key="section_type">TABLE</infon><infon key="type">table_footnote</infon><offset>23902</offset><text>ALP = alkaline phosphatase; ALT = alanine aminotransferase; AST = aspartate aminotransferase; IFN = interferon; IL = interleukin; LDH = lactate dehydrogenase; TNF = tumor necrosis factor; other abbreviations as in Table 1.</text></passage><passage><infon key="file">tbl4.xml</infon><infon key="id">tbl4</infon><infon key="section_type">TABLE</infon><infon key="type">table_footnote</infon><offset>24140</offset><text>Number of missing values.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>24166</offset><text>Twenty-five patients (66%) met the MIS-A criteria (Table 1). By definition, MIS-A+ patients had more frequent fever, skin rash, enanthema, pharyngitis, and conjunctivitis, as compared with MIS-A− patients (Table 1). In addition, they had, as expected by the MIS-A definition, higher levels of systemic inflammation markers, including circulating leukocytes, procalcitonin, C-reactive protein, and fibrinogen (Table 4 ).</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>24591</offset><text>The median delay between COVID-19 symptoms onset and occurrence of myocarditis was shorter in MIS-A− patients: 3 vs 8 days. Noteworthy, the delay between first COVID-19 symptoms and myocarditis was 32 days (IQR: 25-44 days) among the 12 MIS-A+ patients with prior proven symptomatic SARS-CoV-2 infection. The rate of positive serology was lower in MIS-A− patients (15% vs 96%), and their titer was also much lower than in MIS-A+ patients (P &lt; 0.0001). Conversely, positive nasopharyngeal RT-PCR at the time of myocarditis was infrequent in MIS-A+ patients (16%), as compared with MIS-A− patients (85%).</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>25202</offset><text>MIS-A− patients had swifter ICU admission after myocarditis onset (1 vs 4 days) with a more severe presentation (day 0 Sequential Organ Failure Assessment score of 11 vs 6 in MIS-A+ patients). They had a lower LVEF (10% vs 30%) and LVOT-VTI (5 cm vs 13 cm) (Table 2) and were more likely to receive norepinephrine, mechanical ventilation, and renal replacement therapy. Large pericardial effusions were also more frequently observed in MIS-A− patients. The median lactate level was 5.5 vs 2.1 mmol/L in MIS-A− and MIS-A+ patients, respectively. Finally, MIS-A− patients were more likely to require VA-ECMO than MIS-A+ patients (92% vs 16%), and had a higher in-ICU mortality (31% vs 4%; P = 0.04) (Table 3). The 3-month cumulative probabilities of survival ± standard error for MIS-A− and MIS-A+ patients were, respectively, 68% ± 13% and 96% ± 4%; log-rank test P = 0.01.</text></passage><passage><infon key="file">gr1_lrg.jpg</infon><infon key="id">fig1</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>26097</offset><text>Circulating Cytokines Levels in Fulminant COVID-19–Related Myocarditis</text></passage><passage><infon key="file">gr1_lrg.jpg</infon><infon key="id">fig1</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>26170</offset><text>Comparison of 6 circulating serum cytokines levels (IL-8, -10, -17, -22, IFN-α2, and TNF-α) in patients with MIS-A+/MIS-A− and healthy controls. MIS-A+ had higher IL-22, IL-17, and TNF-α, whereas MIS-A− had higher IFN-α2 and IL-8. Methods: serum concentrations of IL-8, IL-10, IL-22 and TNF-α were measured on a Quanterix SP-X imaging and analysis platform using the Human CorPlex Cytokine Panel Array kit (Quanterix). Single-plex bead-based ultrasensitive immunodetection of IL-17A and IFN-α was performed by digital ELISA using the Simoa (single molecule array) HD-1 analyzer (Quanterix), according to the manufacturer’s instructions. For box and whisker plots: the center line denotes the median value (50th percentile), whereas the box contains the 25th to 75th percentiles of dataset. The whiskers mark the 5th and 95th percentiles. IFN = interferon; IL = interleukin; MIS-A = multisystem inflammatory syndrome in adults; TNF = tumor necrosis factor.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>27150</offset><text>Cytokine profiling highlighted the presence of 2 distinct cytokine production profiles (Figure 1 , Table 4): MIS-A+ had higher IL-22 (9.93 vs 1.5 pg/mL; P &lt; 0.0001), IL-17 (3.2 vs 0.15 pg/mL; P &lt; 0.0001), and TNF-α (21.1 vs 8.0 pg/mL; P = 0.05) levels, as compared with MIS-A− patients, whereas the latter had higher IFN-α2 (2.4 vs 0.013 pg/mL; P = 0.001) and IL-8 (158.7 vs 65.7 pg/mL; P = 0.02), respectively. Moreover, RNA polymerase III autoantibodies were found in 7 MIS-A− patients (54%), 5 of them being female (Table 4).</text></passage><passage><infon key="file">gr2_lrg.jpg</infon><infon key="id">fig2</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>27696</offset><text>PCA of Parameters Associated With COVID-19–Related Myocarditis</text></passage><passage><infon key="file">gr2_lrg.jpg</infon><infon key="id">fig2</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>27761</offset><text>Unsupervised PCA was performed using R software v3.6.2 with the FactoExtra and FactoMineR functions, on z-scaled log10-transformed cytokine concentrations. Samples with missing data were excluded from the PCA analysis for 1 MIS-A+ patient and 2 MIS-A− patients. Ellipses with 66% CI are drawn for each group. (A) The principal component analysis of 10 circulating serum cytokines. (B) The principal component analysis including clinical findings, laboratory findings and immunological profiles highlight the main features of MIS-A− and MIS-A+ fulminant COVID-19–related myocarditis phenotypes. CRP = C-reactive protein; LVEF = left ventricular ejection fraction; PCA = principal component analysis; RT-PCR = reverse transcription polymerase chain reaction; SOFA = Sequential Organ Failure Assessment; other abbreviations as in Figure 1.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>28614</offset><text>Finally, to elucidate the relative importance of the various bioclinical parameters listed in the preceding text with the clinical profile of MIS-A+ or MIS-A− patients, we performed nonsupervised PCA using study parameters contributing, in a statistically significant manner, to interpatient variation (Tables 1, 2, and 3). The results from PCA underlined important overall differences between MIS-A+ and MIS-A− patients (Figure 2 ). The data also further highlight parameters most contributing to either clinical status, that is, fibrinogen (P &lt; 0.0001), CRP (P &lt; 0.0001), IL-17 (P &lt; 0.0001), IL-22 (P &lt; 0.0001), IFN-α2 (P = 0.001) levels, SARS-CoV-2 serology (P &lt; 0.0001), and SARS-CoV-2 RT-PCR (P &lt; 0.0001), LVEF (P = 0.01) values on admission, and the presence of RNA polymerase III autoantibodies (P = 0.001).</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">title_1</infon><offset>29448</offset><text>Discussion</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>29459</offset><text>In this retrospective monocenter cohort of fulminant COVID-19–related myocarditis, we applied the MIS-A criteria case definition, and we identified 2 subsets of patients with very different clinical/biological presentations, outcomes, and immunological profiles. This phenotypic heterogeneity being likely explained by important differences in pathophysiological mechanisms.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>29836</offset><text>The patients in this cohort were mostly young men with severely impaired cardiac function, frequently requiring VA-ECMO, with infrequent concomitant COVID-19–associated pneumonia. All survivors recovered a near normal cardiac function at distant follow-up. To our knowledge, this study is the largest cohort of COVID-19–related fulminant myocarditis and extends prior reports of COVID-19–related myocarditis   and fulminant non–COVID-19 myocarditis.   </text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>30297</offset><text>This analysis underscores the major clinical and immunological differences between patients with fulminant COVID-19–related myocarditis fulfilling or not MIS-A criteria. The original description of MIS-C was reported in May 2020, and MIS-A, a few months afterwards.     This somewhat delayed description, together with the rarity of the disease, may have participated to an under-recognition of MIS in the adult population. Furthermore, whereas MIS-C is now well-defined with classification criteria established by the World Health Organization and the Centers for Disease Control and Prevention,   only the latter has adapted its criteria to the adult population. </text></passage><passage><infon key="file">gr3_lrg.jpg</infon><infon key="id">undfig2</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>30965</offset><text>Main Phenotypic Differences Between Fulminant COVID-19–Related Myocarditis With and Without Multisystem Inflammatory Syndrome in Adults</text></passage><passage><infon key="file">gr3_lrg.jpg</infon><infon key="id">undfig2</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>31103</offset><text>MIS-A+ and MIS-A− fulminant COVID-19–related myocarditis patients have 2 distinct phenotypes with different clinical presentations, prognosis and immunological profiles. For box and whisker plots: the center line denotes the median value (50th percentile), whereas the box contains the 25th to 75th percentiles of dataset. The whiskers mark the 5th and 95th percentiles. ICU = intensive care unit; MIS-A = multisystem inflammatory syndrome in adults; RT-PCR = reverse transcription polymerase chain reaction; U.S.-CDC = U.S. Centers for Disease Control and Protection.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>31682</offset><text>The main differences between the phenotypes of MIS-A+ and MIS-A− patients are summarized in the Central Illustration . MIS-A+ COVID-19–related myocarditis appears to be a postinfectious complication of SARS-CoV-2 infection, as suggested by the higher delay between COVID-19 symptoms and myocarditis, as well as by frequently positive serology and negative (or slightly positive) RT-PCR. Mucocutaneous manifestations are frequent in addition to laboratory evidence of severe systemic inflammation. Heart failure is more progressive, leading to fewer accounts of refractory cardiogenic shock, and is associated with a lower mortality rate. Conversely, MIS-A− fulminant COVID-19–related myocarditis occurred at the early phase of SARS-CoV-2 infection (negative or slightly positive serology and positive RT-PCR) with an explosive and refractory cardiogenic shock in nearly all patients leading to high morbidity and mortality.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>32614</offset><text>Interestingly, these different clinical phenotypes are supported by immunological findings. The frequency of RNA polymerase III autoantibodies is high in MIS-A−, whereas it is absent in MIS-A+ patients. The presence of these rare autoantibodies, usually associated with severe systemic sclerosis, has been previously reported by Pineton de Chambrun et al in patients with severe recurrent myocarditis and/or pericarditis, especially related to influenza virus. The role of these autoantibodies in the susceptibility to viral myocarditis is not yet elucidated. Their presence might reflect altered immune defenses toward viral infections or, alternatively, exaggerated antiviral responses leading to organ damage. Another patient with recurrent viral myocarditis, including COVID-19–related myocarditis, has been recently reported. </text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>33451</offset><text>The cytokine profiles of these patients were also found definitely different in the 2 clinical phenotypes (Figure 2). In MIS-A− patients, high levels of systemic circulating antiviral IFN-α2 likely arise from the ongoing viral infection, in relation to detectable viral replication and yet undetectable anti–SARS-CoV-2 IgG humoral responses. Levels of IL-8, a proinflammatory cytokine, were also more elevated in MIS-A−, as compared with MIS-A+ patients, further underlining the dominance of an innate type of immune response in the former group. Conversely, elevated IL-17 and IL-22 levels were found particularly associated with the MIS-A+ phenotype, in agreement with the mucocutaneous manifestations observed in these patients. IL-17 and IL-22 shape innate defenses at mucosal and epithelial surfaces, IL-17 being proinflammatory and involved in the pathogenesis of several autoimmune diseases, whereas the latter cytokine is playing an important role in tissue regeneration. Of note, the extremely high serum IL-10 levels observed in both MIS-A− and MIS-A+ patients have been previously associated with severe myocardial injury and increased risk of death in severe COVID-19 patients. </text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>34652</offset><text>MIS pathogenesis is not fully understood, but the delay between SARS-CoV-2 infection and disease onset, and overexpression of mucosal T cell cytokines (IL-22 and IL-17) suggest a role for the adaptive immune response in MIS-A+ patients. Conversely, in MIS-A− cases, innate antiviral immunity and/or direct toxicity of the virus are more likely involved in heart tissue injury. In our series, SARS-CoV-2 RT-PCR on 2 MIS-A− endomyocardial biopsies (EMBs) were negative. This is in line with previous cases reports,   even if positive SARS-CoV-2 RT-PCR in myocardial samples has also been sporadically reported.   To the best of our knowledge, only 1 study demonstrated the presence of viral particles in cardiomyocytes by electronical microscopy, with only mild interstitial inflammatory infiltrate and no necrosis or microthrombosis, thereby suggesting that the underlying mechanism of myocarditis development was mainly related to a virus-mediated immune response. The EMBs published results from fulminant COVID-19–related myocarditis often reported important myocardial edema with no or mild inflammatory infiltrate or necrosis,   a finding that is also consistent with CMR observations.   </text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>35851</offset><text>The phenotypic clustering of patients with fulminant COVID-19–related myocarditis seems relevant for their management. Indeed, MIS-A− cases, owing to the high risk of evolution toward refractory cardiogenic shock, should be urgently referred to a center with VA-ECMO capability and closely monitored to avoid a too-late cannulation, especially under cardiopulmonary resuscitation, known to be associated with poor outcome. The 5 patients who died in our series had late VA-ECMO implantation, while having multiple organ failure or under resuscitation. Conversely, the risk of evolution toward refractory cardiogenic shock is lower in MIS-A+ cases. Our results are consistent with those of a large series of 186 MIS-C from the United States, where only 8 patients required VA-ECMO and 4 died. MIS-A+ patient identification is all the more important given that numerous data support the efficacy of corticosteroids and/or intravenous immunoglobulins in MIS-C. Best treatment regimen is yet to be determined because conflicting results have been reported with standalone or combination treatment.   However, one should take with caution the results of nonrandomized/nonblinded therapeutic intervention in a disease where spontaneous recovery occurs in most patients in a few days.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">title_2</infon><offset>37133</offset><text>Study limitations</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>37151</offset><text>First, the external validity is limited by its monocentric and retrospective nature. Notably, as an ECMO center, there might be a selection bias toward the inclusion of the most severe patients. Second, although being the largest series of fulminant COVID-19–related myocarditis, the sample size remains small, limiting the power of the study. Lastly, EMBs were performed in only 3 patients, whereas expert consensus and guidelines recommend to consider EMB in fulminant presentation for its diagnostic and therapeutic implications. However, coagulation disorders are frequent in COVID-19–related myocarditis and VA-ECMO patients. The benefit/risk ratio was evaluated against EMB in all but 3 cases, especially given the known diagnosis of SARS-CoV-2 infection. It is nevertheless unfortunate that we cannot provide a more extensive characterization of COVID-19–related myocarditis histopathological findings in MIS-A+ and MIS-A− patients.</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">title_1</infon><offset>38099</offset><text>Conclusions</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>38111</offset><text>COMPETENCY IN PATIENT CARE AND PROCEDURAL SKILLS: MIS-A criteria distinguish phenotypes of patients who develop fulminant myocarditis related to COVID-19, with different clinical presentations, immunological profiles, and outcomes. Those with MIS-A criteria more often have elevated serum levels of IL-17 and IL-22 while those without are frequently positive for serum RNA polymerase III autoantibodies, have high serum level of IFN-α and more often require ECMO.</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>38579</offset><text>TRANSLATIONAL OUTLOOK: Further investigation is needed to characterize the role of RNA-polymerase-III antibodies in the pathophysiology of MIS-A COVID-19–related fulminant myocarditis.</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>38766</offset><text>We identified 2 phenotypes of fulminant COVID-19–related myocarditis harboring distinct clinical and laboratory manifestations, evolutions, and outcomes. Differentiating these patients seems relevant for their management and for further pathophysiological studies. The role of RNA polymerase III autoantibodies in fulminant myocarditis requires further investigation. </text></passage><passage><infon key="section_type">ACK_FUND</infon><infon key="type">title_1</infon><offset>39137</offset><text>Funding Support and Author Disclosures</text></passage><passage><infon key="section_type">ACK_FUND</infon><infon key="type">paragraph</infon><offset>39176</offset><text>This study was supported by the Fondation de France, ‘‘Tous unis contre le virus’’ framework Alliance (Fondation de France, AP-HP, Institut Pasteur) in collaboration with Agence Nationale de la Recherche (ANR Flash COVID19 program), by the SARS-CoV-2 Program of the Faculty of Medicine from Sorbonne University ICOViD programs, by the Programme Hospitalier de Recherche Clinique PHRC-20-0375 COVID-19 (principal investigator D Gorochov). The authors declare that a patent application has been filed on these results. Dr Pineton de Chambrun was supported for this study by a grant from la Société Française Nationale de Médecine Interne (SNFMI-2021). Dr Pineton de Chambrun has received a research grant from Octapharma; and has received lecture fees from Sanofi. Dr Kerneis has received research grants from the Fédération Française de Cardiologie, French Ministry of Health; and has received consulting fees from Bayer, Sanofi, and Kiniksa. Dr Montalescot has received research grants from Abbott, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, Cell Prothera, CSL Behring, Europa, Idorsia, IRIS-Servier, Medtronic, Merck Sharp and Dohme, Novartis, Pfizer, Quantum Genomics, and Sanofi. Dr Combes has received grants and personal fees from Maquet, Xenios, and Baxter outside the submitted work. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">title</infon><offset>40651</offset><text>References</text></passage><passage><infon key="fpage">206</infon><infon key="issue">2</infon><infon key="name_0">surname:Hu;given-names:H.</infon><infon key="name_1">surname:Ma;given-names:F.</infon><infon key="name_2">surname:Wei;given-names:X.</infon><infon key="name_3">surname:Fang;given-names:Y.</infon><infon key="pub-id_doi">10.1093/eurheartj/ehaa190</infon><infon key="pub-id_pmid">32176300</infon><infon key="section_type">REF</infon><infon key="source">Eur Heart J</infon><infon key="type">ref</infon><infon key="volume">42</infon><infon key="year">2021</infon><offset>40662</offset><text>Coronavirus fulminant myocarditis saved with glucocorticoid and human immunoglobulin</text></passage><passage><infon key="fpage">1861</infon><infon key="lpage">1862</infon><infon key="name_0">surname:Sala;given-names:S.</infon><infon key="name_1">surname:Peretto;given-names:G.</infon><infon key="name_2">surname:Gramegna;given-names:M.</infon><infon key="pub-id_pmid">32267502</infon><infon key="section_type">REF</infon><infon key="source">Eur Heart J</infon><infon key="type">ref</infon><infon key="volume">41</infon><infon key="year">2020</infon><offset>40747</offset><text>Acute myocarditis presenting as a reverse Tako-Tsubo syndrome in a patient with SARS-CoV-2 respiratory infection</text></passage><passage><infon key="fpage">911</infon><infon key="lpage">915</infon><infon key="name_0">surname:Tavazzi;given-names:G.</infon><infon key="name_1">surname:Pellegrini;given-names:C.</infon><infon key="name_2">surname:Maurelli;given-names:M.</infon><infon key="pub-id_pmid">32275347</infon><infon key="section_type">REF</infon><infon key="source">Eur J Heart Fail</infon><infon key="type">ref</infon><infon key="volume">22</infon><infon key="year">2020</infon><offset>40860</offset><text>Myocardial localization of coronavirus in COVID-19 cardiogenic shock</text></passage><passage><infon key="fpage">773</infon><infon key="issue">5</infon><infon key="lpage">777</infon><infon key="name_0">surname:Zeng;given-names:J.-H.</infon><infon key="name_1">surname:Liu;given-names:Y.-X.</infon><infon key="name_2">surname:Yuan;given-names:J.</infon><infon key="pub-id_doi">10.1007/s15010-020-01424-5</infon><infon key="pub-id_pmid">32277408</infon><infon key="section_type">REF</infon><infon key="source">Infection</infon><infon key="type">ref</infon><infon key="volume">48</infon><infon key="year">2020</infon><offset>40929</offset><text>First case of COVID-19 complicated with fulminant myocarditis: a case report and insights</text></passage><passage><infon key="fpage">1342</infon><infon key="lpage">1346</infon><infon key="name_0">surname:Garot;given-names:J.</infon><infon key="name_1">surname:Amour;given-names:J.</infon><infon key="name_2">surname:Pezel;given-names:T.</infon><infon key="section_type">REF</infon><infon key="source">J Am Coll Cardiol Case Rep</infon><infon key="type">ref</infon><infon key="volume">2</infon><infon key="year">2020</infon><offset>41019</offset><text>SARS-CoV-2 fulminant myocarditis</text></passage><passage><infon key="comment">3021-3021</infon><infon key="name_0">surname:Kesici;given-names:S.</infon><infon key="name_1">surname:Aykan;given-names:H.H.</infon><infon key="name_2">surname:Orhan;given-names:D.</infon><infon key="name_3">surname:Bayrakci;given-names:B.</infon><infon key="section_type">REF</infon><infon key="source">Eur Heart J</infon><infon key="type">ref</infon><infon key="volume">41</infon><infon key="year">2020</infon><offset>41052</offset><text>Fulminant COVID-19-related myocarditis in an infant</text></passage><passage><infon key="fpage">1029</infon><infon key="lpage">1035</infon><infon key="name_0">surname:Mirabel;given-names:M.</infon><infon key="name_1">surname:Luyt;given-names:C.-E.</infon><infon key="name_2">surname:Leprince;given-names:P.</infon><infon key="pub-id_pmid">21336134</infon><infon key="section_type">REF</infon><infon key="source">Crit Care Med</infon><infon key="type">ref</infon><infon key="volume">39</infon><infon key="year">2011</infon><offset>41104</offset><text>Outcomes, long-term quality of life, and psychologic assessment of fulminant myocarditis patients rescued by mechanical circulatory support</text></passage><passage><infon key="fpage">1607</infon><infon key="issue">10237</infon><infon key="lpage">1608</infon><infon key="name_0">surname:Riphagen;given-names:S.</infon><infon key="name_1">surname:Gomez;given-names:X.</infon><infon key="name_2">surname:Gonzalez-Martinez;given-names:C.</infon><infon key="name_3">surname:Wilkinson;given-names:N.</infon><infon key="name_4">surname:Theocharis;given-names:P.</infon><infon key="pub-id_doi">10.1016/S0140-6736(20)31094-1</infon><infon key="pub-id_pmid">32386565</infon><infon key="section_type">REF</infon><infon key="source">Lancet</infon><infon key="type">ref</infon><infon key="volume">395</infon><infon key="year">2020</infon><offset>41244</offset><text>Hyperinflammatory shock in children during COVID-19 pandemic</text></passage><passage><infon key="fpage">657</infon><infon key="issue">2</infon><infon key="lpage">662</infon><infon key="name_0">surname:Hékimian;given-names:G.</infon><infon key="name_1">surname:Kerneis;given-names:M.</infon><infon key="name_2">surname:Zeitouni;given-names:M.</infon><infon key="pub-id_doi">10.1016/j.chest.2020.08.2099</infon><infon key="pub-id_pmid">32910974</infon><infon key="section_type">REF</infon><infon key="source">Chest</infon><infon key="type">ref</infon><infon key="volume">159</infon><infon key="year">2021</infon><offset>41305</offset><text>COVID-19 acute myocarditis and multisystem inflammatory syndrome in adult intensive and cardiac care units</text></passage><passage><infon key="comment">Accessed November 1, 2021.</infon><infon key="element-citation">https://www.cdc.gov/mis/mis-a/hcp.html</infon><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>41412</offset><text>Centers for Disease Control and Prevention. Multisystem inflammatory syndrome in adults (MIS-A) case definition information for healthcare providers</text></passage><passage><infon key="fpage">80</infon><infon key="lpage">91</infon><infon key="name_0">surname:Bonaca;given-names:M.P.</infon><infon key="name_1">surname:Olenchock;given-names:B.A.</infon><infon key="name_2">surname:Salem;given-names:J.-E.</infon><infon key="pub-id_pmid">31390169</infon><infon key="section_type">REF</infon><infon key="source">Circulation</infon><infon key="type">ref</infon><infon key="volume">140</infon><infon key="year">2019</infon><offset>41561</offset><text>Myocarditis in the setting of cancer therapeutics: proposed case definitions for emerging clinical syndromes in cardio-oncology</text></passage><passage><infon key="fpage">e116</infon><infon key="name_0">surname:Gnecchi;given-names:M.</infon><infon key="name_1">surname:Moretti;given-names:F.</infon><infon key="name_2">surname:Bassi;given-names:E.M.</infon><infon key="pub-id_pmid">32593338</infon><infon key="section_type">REF</infon><infon key="source">Lancet</infon><infon key="type">ref</infon><infon key="volume">395</infon><infon key="year">2020</infon><offset>41689</offset><text>Myocarditis in a 16-year-old boy positive for SARS-CoV-2</text></passage><passage><infon key="fpage">1516</infon><infon key="name_0">surname:Doyen;given-names:D.</infon><infon key="name_1">surname:Moceri;given-names:P.</infon><infon key="name_2">surname:Ducreux;given-names:D.</infon><infon key="name_3">surname:Dellamonica;given-names:J.</infon><infon key="pub-id_pmid">32334650</infon><infon key="section_type">REF</infon><infon key="source">Lancet</infon><infon key="type">ref</infon><infon key="volume">395</infon><infon key="year">2020</infon><offset>41746</offset><text>Myocarditis in a patient with COVID-19: a cause of raised troponin and ECG changes</text></passage><passage><infon key="fpage">251</infon><infon key="issue">1</infon><infon key="lpage">261</infon><infon key="name_0">surname:Castiello;given-names:T.</infon><infon key="name_1">surname:Georgiopoulos;given-names:G.</infon><infon key="name_2">surname:Finocchiaro;given-names:G.</infon><infon key="pub-id_doi">10.1007/s10741-021-10087-9</infon><infon key="pub-id_pmid">33761041</infon><infon key="section_type">REF</infon><infon key="source">Heart Fail Rev</infon><infon key="type">ref</infon><infon key="volume">27</infon><infon key="year">2022</infon><offset>41829</offset><text>COVID-19 and myocarditis: a systematic review and overview of current challenges</text></passage><passage><infon key="fpage">681</infon><infon key="lpage">685</infon><infon key="name_0">surname:Ho;given-names:J.S.</infon><infon key="name_1">surname:Sia;given-names:C.-H.</infon><infon key="name_2">surname:Chan;given-names:M.Y.</infon><infon key="name_3">surname:Lin;given-names:W.</infon><infon key="name_4">surname:Wong;given-names:R.C.</infon><infon key="section_type">REF</infon><infon key="source">Heart Lung J Crit Care</infon><infon key="type">ref</infon><infon key="volume">49</infon><infon key="year">2020</infon><offset>41910</offset><text>Coronavirus-induced myocarditis: a meta-summary of cases</text></passage><passage><infon key="fpage">299</infon><infon key="lpage">311</infon><infon key="name_0">surname:Ammirati;given-names:E.</infon><infon key="name_1">surname:Veronese;given-names:G.</infon><infon key="name_2">surname:Brambatti;given-names:M.</infon><infon key="pub-id_pmid">31319912</infon><infon key="section_type">REF</infon><infon key="source">J Am Coll Cardiol</infon><infon key="type">ref</infon><infon key="volume">74</infon><infon key="year">2019</infon><offset>41967</offset><text>Fulminant versus acute nonfulminant myocarditis in patients with left ventricular systolic dysfunction</text></passage><passage><infon key="fpage">919</infon><infon key="lpage">926</infon><infon key="name_0">surname:Lorusso;given-names:R.</infon><infon key="name_1">surname:Centofanti;given-names:P.</infon><infon key="name_2">surname:Gelsomino;given-names:S.</infon><infon key="pub-id_pmid">26518372</infon><infon key="section_type">REF</infon><infon key="source">Ann Thorac Surg</infon><infon key="type">ref</infon><infon key="volume">101</infon><infon key="year">2016</infon><offset>42070</offset><text>Venoarterial extracorporeal membrane oxygenation for acute fulminant myocarditis in adult patients: a 5-year multi-institutional experience</text></passage><passage><infon key="fpage">61</infon><infon key="lpage">64</infon><infon key="name_0">surname:Hékimian;given-names:G.</infon><infon key="name_1">surname:Jovanovic;given-names:T.</infon><infon key="name_2">surname:Bréchot;given-names:N.</infon><infon key="pub-id_pmid">29929152</infon><infon key="section_type">REF</infon><infon key="source">J Crit Care</infon><infon key="type">ref</infon><infon key="volume">47</infon><infon key="year">2018</infon><offset>42210</offset><text>When the heart gets the flu: fulminant influenza B myocarditis: a case-series report and review of the literature</text></passage><passage><infon key="fpage">529</infon><infon key="lpage">545</infon><infon key="name_0">surname:Ammirati;given-names:E.</infon><infon key="name_1">surname:Cipriani;given-names:M.</infon><infon key="name_2">surname:Lilliu;given-names:M.</infon><infon key="pub-id_pmid">28576783</infon><infon key="section_type">REF</infon><infon key="source">Circulation</infon><infon key="type">ref</infon><infon key="volume">136</infon><infon key="year">2017</infon><offset>42324</offset><text>Survival and left ventricular function changes in fulminant versus nonfulminant acute myocarditis</text></passage><passage><infon key="fpage">e8</infon><infon key="lpage">e10</infon><infon key="name_0">surname:Shaigany;given-names:S.</infon><infon key="name_1">surname:Gnirke;given-names:M.</infon><infon key="name_2">surname:Guttmann;given-names:A.</infon><infon key="pub-id_pmid">32659211</infon><infon key="section_type">REF</infon><infon key="source">Lancet</infon><infon key="type">ref</infon><infon key="volume">396</infon><infon key="year">2020</infon><offset>42422</offset><text>An adult with Kawasaki-like multisystem inflammatory syndrome associated with COVID-19</text></passage><passage><infon key="fpage">1450</infon><infon key="lpage">1456</infon><infon key="name_0">surname:Morris;given-names:S.B.</infon><infon key="name_1">surname:Schwartz;given-names:N.G.</infon><infon key="name_2">surname:Patel;given-names:P.</infon><infon key="pub-id_pmid">33031361</infon><infon key="section_type">REF</infon><infon key="source">MMWR Morb Mortal Wkly Rep</infon><infon key="type">ref</infon><infon key="volume">69</infon><infon key="year">2020</infon><offset>42509</offset><text>Case series of multisystem inflammatory syndrome in adults associated with SARS-CoV-2 infection - United Kingdom and United States, March-August 2020</text></passage><passage><infon key="comment">Accessed November 1, 2021.</infon><infon key="element-citation">https://www.who.int/news-room/commentaries/detail/multisystem-inflammatory-syndrome-in-children-and-adolescents-with-covid-19</infon><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>42659</offset><text>World Health Organization. Multisystem inflammatory syndrome in children and adolescents temporally related to COVID-19</text></passage><passage><infon key="comment">Accessed November 1, 2021.</infon><infon key="element-citation">https://www.cdc.gov/mis/mis-c/hcp/index.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fmis%2Fhcp%2Findex.html</infon><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>42779</offset></passage><passage><infon key="fpage">502</infon><infon key="lpage">504</infon><infon key="name_0">surname:Pineton de Chambrun;given-names:M.</infon><infon key="name_1">surname:Charuel;given-names:J.-L.</infon><infon key="name_2">surname:Hékimian;given-names:G.</infon><infon key="pub-id_pmid">31842206</infon><infon key="section_type">REF</infon><infon key="source">Ann Intern Med</infon><infon key="type">ref</infon><infon key="volume">172</infon><infon key="year">2020</infon><offset>42780</offset><text>Severe viral myopericarditis with autoantibodies directed against RNA polymerase III</text></passage><passage><infon key="fpage">756</infon><infon key="lpage">760</infon><infon key="name_0">surname:Caraffa;given-names:R.</infon><infon key="name_1">surname:Marcolongo;given-names:R.</infon><infon key="name_2">surname:Bottio;given-names:T.</infon><infon key="pub-id_pmid">33225579</infon><infon key="section_type">REF</infon><infon key="source">ESC Heart Fail</infon><infon key="type">ref</infon><infon key="volume">8</infon><infon key="year">2021</infon><offset>42865</offset><text>Recurrent autoimmune myocarditis in a young woman during the coronavirus disease 2019 pandemic</text></passage><passage><infon key="fpage">354</infon><infon key="lpage">361</infon><infon key="name_0">surname:Eyerich;given-names:S.</infon><infon key="name_1">surname:Eyerich;given-names:K.</infon><infon key="name_2">surname:Cavani;given-names:A.</infon><infon key="name_3">surname:Schmidt-Weber;given-names:C.</infon><infon key="pub-id_pmid">20691634</infon><infon key="section_type">REF</infon><infon key="source">Trends Immunol</infon><infon key="type">ref</infon><infon key="volume">31</infon><infon key="year">2010</infon><offset>42960</offset><text>IL-17 and IL-22: siblings, not twins</text></passage><passage><infon key="fpage">1292</infon><infon key="lpage">1297</infon><infon key="name_0">surname:Nishii;given-names:M.</infon><infon key="name_1">surname:Inomata;given-names:T.</infon><infon key="name_2">surname:Takehana;given-names:H.</infon><infon key="pub-id_pmid">15364334</infon><infon key="section_type">REF</infon><infon key="source">J Am Coll Cardiol</infon><infon key="type">ref</infon><infon key="volume">44</infon><infon key="year">2004</infon><offset>42997</offset><text>Serum levels of interleukin-10 on admission as a prognostic predictor of human fulminant myocarditis</text></passage><passage><infon key="fpage">2098</infon><infon key="lpage">2107</infon><infon key="name_0">surname:Dorgham;given-names:K.</infon><infon key="name_1">surname:Quentric;given-names:P.</infon><infon key="name_2">surname:Gökkaya;given-names:M.</infon><infon key="pub-id_pmid">33894209</infon><infon key="section_type">REF</infon><infon key="source">J Allergy Clin Immunol</infon><infon key="type">ref</infon><infon key="volume">147</infon><infon key="year">2021</infon><offset>43098</offset><text>Distinct cytokine profiles associated with COVID-19 severity and mortality</text></passage><passage><infon key="name_0">surname:Weckbach;given-names:L.T.</infon><infon key="name_1">surname:Curta;given-names:A.</infon><infon key="name_2">surname:Bieber;given-names:S.</infon><infon key="section_type">REF</infon><infon key="source">Circ Cardiovasc Imaging</infon><infon key="type">ref</infon><infon key="volume">14</infon><infon key="year">2021</infon><offset>43173</offset><text>Myocardial inflammation and dysfunction in COVID-19-associated myocardial injury</text></passage><passage><infon key="fpage">2440</infon><infon key="issue">5</infon><infon key="lpage">2447</infon><infon key="name_0">surname:Escher;given-names:F.</infon><infon key="name_1">surname:Pietsch;given-names:H.</infon><infon key="name_2">surname:Aleshcheva;given-names:G.</infon><infon key="pub-id_doi">10.1002/ehf2.12805</infon><infon key="pub-id_pmid">32529795</infon><infon key="section_type">REF</infon><infon key="source">ESC Heart Fail</infon><infon key="type">ref</infon><infon key="volume">7</infon><infon key="year">2020</infon><offset>43254</offset><text>Detection of viral SARS-CoV-2 genomes and histopathological changes in endomyocardial biopsies</text></passage><passage><infon key="fpage">1865</infon><infon key="lpage">1870</infon><infon key="name_0">surname:Albert;given-names:C.L.</infon><infon key="name_1">surname:Carmona-Rubio;given-names:A.E.</infon><infon key="name_2">surname:Weiss;given-names:A.J.</infon><infon key="name_3">surname:Procop;given-names:G.G.</infon><infon key="name_4">surname:Starling;given-names:R.C.</infon><infon key="name_5">surname:Rodriguez;given-names:E.R.</infon><infon key="pub-id_pmid">32997947</infon><infon key="section_type">REF</infon><infon key="source">Circulation</infon><infon key="type">ref</infon><infon key="volume">142</infon><infon key="year">2020</infon><offset>43349</offset><text>The enemy within: sudden-onset reversible cardiogenic shock with biopsy-proven cardiac myocyte infection by severe acute respiratory syndrome coronavirus 2</text></passage><passage><infon key="fpage">2457</infon><infon key="lpage">2459</infon><infon key="name_0">surname:Salamanca;given-names:J.</infon><infon key="name_1">surname:Díez-Villanueva;given-names:P.</infon><infon key="name_2">surname:Martínez;given-names:P.</infon><infon key="section_type">REF</infon><infon key="source">J Am Coll Cardiol Img</infon><infon key="type">ref</infon><infon key="volume">13</infon><infon key="year">2020</infon><offset>43505</offset><text>COVID-19 “fulminant myocarditis” successfully treated with temporary mechanical circulatory support</text></passage><passage><infon key="fpage">1404</infon><infon key="lpage">1411</infon><infon key="name_0">surname:Combes;given-names:A.</infon><infon key="name_1">surname:Leprince;given-names:P.</infon><infon key="name_2">surname:Luyt;given-names:C.-E.</infon><infon key="pub-id_pmid">18434909</infon><infon key="section_type">REF</infon><infon key="source">Crit Care Med</infon><infon key="type">ref</infon><infon key="volume">36</infon><infon key="year">2008</infon><offset>43609</offset><text>Outcomes and long-term quality-of-life of patients supported by extracorporeal membrane oxygenation for refractory cardiogenic shock</text></passage><passage><infon key="fpage">347</infon><infon key="lpage">358</infon><infon key="name_0">surname:Dufort;given-names:E.M.</infon><infon key="name_1">surname:Koumans;given-names:E.H.</infon><infon key="name_2">surname:Chow;given-names:E.J.</infon><infon key="pub-id_pmid">32598830</infon><infon key="section_type">REF</infon><infon key="source">N Engl J Med</infon><infon key="type">ref</infon><infon key="volume">383</infon><infon key="year">2020</infon><offset>43742</offset><text>Multisystem inflammatory syndrome in children in New York State</text></passage><passage><infon key="fpage">334</infon><infon key="lpage">346</infon><infon key="name_0">surname:Feldstein;given-names:L.R.</infon><infon key="name_1">surname:Rose;given-names:E.B.</infon><infon key="name_2">surname:Horwitz;given-names:S.M.</infon><infon key="pub-id_pmid">32598831</infon><infon key="section_type">REF</infon><infon key="source">N Engl J Med</infon><infon key="type">ref</infon><infon key="volume">383</infon><infon key="year">2020</infon><offset>43806</offset><text>Multisystem inflammatory syndrome in U.S. children and adolescents</text></passage><passage><infon key="fpage">11</infon><infon key="lpage">22</infon><infon key="name_0">surname:McArdle;given-names:A.J.</infon><infon key="name_1">surname:Vito;given-names:O.</infon><infon key="name_2">surname:Patel;given-names:H.</infon><infon key="pub-id_pmid">34133854</infon><infon key="section_type">REF</infon><infon key="source">N Engl J Med</infon><infon key="type">ref</infon><infon key="volume">385</infon><infon key="year">2021</infon><offset>43873</offset><text>Treatment of multisystem inflammatory syndrome in children</text></passage><passage><infon key="fpage">23</infon><infon key="lpage">34</infon><infon key="name_0">surname:Son;given-names:M.B.F.</infon><infon key="name_1">surname:Murray;given-names:N.</infon><infon key="name_2">surname:Friedman;given-names:K.</infon><infon key="pub-id_pmid">34133855</infon><infon key="section_type">REF</infon><infon key="source">N Engl J Med</infon><infon key="type">ref</infon><infon key="volume">385</infon><infon key="year">2021</infon><offset>43932</offset><text>Multisystem inflammatory syndrome in children - initial therapy and outcomes</text></passage><passage><infon key="comment">2648a-2648d</infon><infon key="fpage">2636</infon><infon key="lpage">2648</infon><infon key="name_0">surname:Caforio;given-names:A.L.P.</infon><infon key="name_1">surname:Pankuweit;given-names:S.</infon><infon key="name_2">surname:Arbustini;given-names:E.</infon><infon key="pub-id_pmid">23824828</infon><infon key="section_type">REF</infon><infon key="source">Eur Heart J</infon><infon key="type">ref</infon><infon key="volume">34</infon><infon key="year">2013</infon><offset>44009</offset><text>Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases</text></passage><passage><infon key="fpage">e69</infon><infon key="lpage">e92</infon><infon key="name_0">surname:Kociol;given-names:R.D.</infon><infon key="name_1">surname:Cooper;given-names:L.T.</infon><infon key="name_2">surname:Fang;given-names:J.C.</infon><infon key="pub-id_pmid">31902242</infon><infon key="section_type">REF</infon><infon key="source">Circulation</infon><infon key="type">ref</infon><infon key="volume">141</infon><infon key="year">2020</infon><offset>44213</offset><text>Recognition and initial management of fulminant myocarditis: a scientific statement from the American Heart Association</text></passage><passage><infon key="name_0">surname:Ammirati;given-names:E.</infon><infon key="name_1">surname:Frigerio;given-names:M.</infon><infon key="name_2">surname:Adler;given-names:E.D.</infon><infon key="section_type">REF</infon><infon key="source">Circ Heart Fail</infon><infon key="type">ref</infon><infon key="volume">13</infon><infon key="year">2020</infon><offset>44333</offset><text>Management of acute myocarditis and chronic inflammatory cardiomyopathy: an expert consensus document</text></passage><passage><infon key="section_type">APPENDIX</infon><infon key="type">title_1</infon><offset>44435</offset><text>Appendix</text></passage><passage><infon key="section_type">APPENDIX</infon><infon key="type">footnote</infon><offset>44444</offset><text>Listen to this manuscript's audio summary by Editor-in-Chief Dr Valentin Fuster onwww.jacc.org/journal/jacc.</text></passage><passage><infon key="section_type">APPENDIX</infon><infon key="type">footnote</infon><offset>44553</offset><text>Andrew Civitello, MD, served as Guest Associate Editor for this paper. Christie M. Ballantyne, MD, served as Guest Editor-in-Chief for this paper.</text></passage><passage><infon key="section_type">APPENDIX</infon><infon key="type">footnote</infon><offset>44700</offset><text>The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the Author Center.</text></passage><passage><infon key="section_type">APPENDIX</infon><infon key="type">footnote</infon><offset>44971</offset><text>Appendix</text></passage><passage><infon key="section_type">APPENDIX</infon><infon key="type">footnote</infon><offset>44980</offset><text>For an expanded Methods section and a supplemental table, please see the online version of this paper.</text></passage></document></collection>
